Jacobi Capital Management LLC Has $688,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

Jacobi Capital Management LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 39.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,159 shares of the company’s stock after acquiring an additional 2,860 shares during the quarter. Jacobi Capital Management LLC’s holdings in AstraZeneca were worth $688,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. BKM Wealth Management LLC acquired a new stake in shares of AstraZeneca during the 4th quarter valued at $243,000. Whittier Trust Co. grew its holdings in shares of AstraZeneca by 6.9% during the fourth quarter. Whittier Trust Co. now owns 19,584 shares of the company’s stock worth $1,319,000 after purchasing an additional 1,257 shares during the last quarter. HB Wealth Management LLC increased its stake in shares of AstraZeneca by 1.3% in the fourth quarter. HB Wealth Management LLC now owns 28,454 shares of the company’s stock valued at $1,916,000 after buying an additional 354 shares during the period. Compagnie Lombard Odier SCmA bought a new position in AstraZeneca in the 4th quarter valued at approximately $27,000. Finally, Cooper Financial Group acquired a new stake in AstraZeneca during the 4th quarter worth approximately $431,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. BMO Capital Markets increased their price target on AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, April 26th. The Goldman Sachs Group initiated coverage on AstraZeneca in a research note on Thursday, May 30th. They issued a “buy” rating and a $97.00 price objective on the stock. Finally, Argus increased their target price on shares of AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $88.00.

AstraZeneca Stock Up 0.6 %

NASDAQ:AZN traded up $0.45 on Monday, hitting $79.16. The stock had a trading volume of 3,521,019 shares, compared to its average volume of 5,308,037. The company has a market cap of $245.44 billion, a PE ratio of 38.80, a P/E/G ratio of 1.42 and a beta of 0.45. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $80.86. The business’s fifty day moving average is $78.39 and its 200 day moving average is $71.68. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, April 25th. The company reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.08. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. The business had revenue of $12.68 billion during the quarter, compared to analyst estimates of $11.92 billion. On average, equities research analysts expect that AstraZeneca PLC will post 4.05 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.